Tags

Type your tag names separated by a space and hit enter

Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial.
BMC Vet Res. 2018 Jun 15; 14(1):186.BV

Abstract

BACKGROUND

Inflammatory and degenerative activity inside the joint can be studied in vivo via analysis of synovial fluid (SF) biomarkers, which are molecular markers of inflammatory processes and tissue turnover. The aim of this study was to investigate the response of selected biomarkers in the SF after an intra-articular (IA) high-molecular-weight non-animal stabilized hyaluronic acid (NASHA) treatment. Our hypothesis was that prostaglandin E2 (PGE2), substance P, aggrecan chondroitin sulfate 846 epitope (CS846), and carboxypeptide of type II collagen (CPII) concentrations in SF would decrease more in the NASHA than in the placebo group. Twenty-eight clinically lame horses with positive responses to diagnostic IA anaesthesia of the metacarpophalangeal or metatarsophalangeal joints were randomized into treatment (n = 15) and control (n = 13) groups. After collection of baseline SF samples followed by IA diagnostic anaesthesia, horses in the treatment group received 3 ml of a NASHA product IA. Those in the placebo group received an equivalent volume of sterile 0.9% saline solution. The horses were re-evaluated and a second SF sample was obtained after a 2-week period.

RESULTS

CS846 concentration decreased in the NASHA group only (P = 0.010). Both PGE2 and CPII concentrations decreased within the groups (PGE2, P = 0.010 for the NASHA group; P = 0.027 for the placebo group; CPII, P < 0.001 for NASHA group; P = 0.009 for placebo group). No significant treatment effect for any biomarker was found between groups. NASHA induced an increase in white blood cell count; this was significant compared with baseline (P = 0.021) and the placebo group (P = 0.045).

CONCLUSIONS

Although the SF concentration of the cartilage-derived biomarker CS846 decreased in the NASHA group, no statistically significant treatment effect of any of the biomarkers were observed between treatment groups. The significant increase in SF white blood cell count after IA NASHA may indicate a mild inflammatory response. However, as no clinical adverse effects were observed, we conclude that IA NASHA was well tolerated.

Authors+Show Affiliations

Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014, Helsinki, Finland. tytti.niemela@fimnet.fi.Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014, Helsinki, Finland.Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014, Helsinki, Finland.Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014, Helsinki, Finland.Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, P.O. Box 57, 00014, Helsinki, Finland.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

29907111

Citation

Niemelä, Tytti M., et al. "Changes in Biomarkers in Equine Synovial Fluid Two Weeks After Intra-articular Hyaluronan Treatment: a Randomised Double-blind Clinical Trial." BMC Veterinary Research, vol. 14, no. 1, 2018, p. 186.
Niemelä TM, Tulamo RM, Aaltonen K, et al. Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial. BMC Vet Res. 2018;14(1):186.
Niemelä, T. M., Tulamo, R. M., Aaltonen, K., Sankari, S. M., & Hielm-Björkman, A. K. (2018). Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial. BMC Veterinary Research, 14(1), 186. https://doi.org/10.1186/s12917-018-1512-2
Niemelä TM, et al. Changes in Biomarkers in Equine Synovial Fluid Two Weeks After Intra-articular Hyaluronan Treatment: a Randomised Double-blind Clinical Trial. BMC Vet Res. 2018 Jun 15;14(1):186. PubMed PMID: 29907111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial. AU - Niemelä,Tytti M, AU - Tulamo,Riitta-Mari, AU - Aaltonen,Kaisa, AU - Sankari,Satu M, AU - Hielm-Björkman,Anna K, Y1 - 2018/06/15/ PY - 2017/02/17/received PY - 2018/06/01/accepted PY - 2018/6/17/entrez PY - 2018/6/17/pubmed PY - 2018/10/5/medline KW - Aggrecan chondroitin sulfate 846 epitope KW - Biomarkers KW - Carboxypeptide of type II collagen KW - Clinical study KW - Non-animal stabilized hyaluronic acid (NASHA) KW - Placebo-controlled KW - Prostaglandin E2 KW - Substance P SP - 186 EP - 186 JF - BMC veterinary research JO - BMC Vet. Res. VL - 14 IS - 1 N2 - BACKGROUND: Inflammatory and degenerative activity inside the joint can be studied in vivo via analysis of synovial fluid (SF) biomarkers, which are molecular markers of inflammatory processes and tissue turnover. The aim of this study was to investigate the response of selected biomarkers in the SF after an intra-articular (IA) high-molecular-weight non-animal stabilized hyaluronic acid (NASHA) treatment. Our hypothesis was that prostaglandin E2 (PGE2), substance P, aggrecan chondroitin sulfate 846 epitope (CS846), and carboxypeptide of type II collagen (CPII) concentrations in SF would decrease more in the NASHA than in the placebo group. Twenty-eight clinically lame horses with positive responses to diagnostic IA anaesthesia of the metacarpophalangeal or metatarsophalangeal joints were randomized into treatment (n = 15) and control (n = 13) groups. After collection of baseline SF samples followed by IA diagnostic anaesthesia, horses in the treatment group received 3 ml of a NASHA product IA. Those in the placebo group received an equivalent volume of sterile 0.9% saline solution. The horses were re-evaluated and a second SF sample was obtained after a 2-week period. RESULTS: CS846 concentration decreased in the NASHA group only (P = 0.010). Both PGE2 and CPII concentrations decreased within the groups (PGE2, P = 0.010 for the NASHA group; P = 0.027 for the placebo group; CPII, P < 0.001 for NASHA group; P = 0.009 for placebo group). No significant treatment effect for any biomarker was found between groups. NASHA induced an increase in white blood cell count; this was significant compared with baseline (P = 0.021) and the placebo group (P = 0.045). CONCLUSIONS: Although the SF concentration of the cartilage-derived biomarker CS846 decreased in the NASHA group, no statistically significant treatment effect of any of the biomarkers were observed between treatment groups. The significant increase in SF white blood cell count after IA NASHA may indicate a mild inflammatory response. However, as no clinical adverse effects were observed, we conclude that IA NASHA was well tolerated. SN - 1746-6148 UR - https://www.unboundmedicine.com/medline/citation/29907111/Changes_in_biomarkers_in_equine_synovial_fluid_two_weeks_after_intra_articular_hyaluronan_treatment:_a_randomised_double_blind_clinical_trial_ L2 - https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-018-1512-2 DB - PRIME DP - Unbound Medicine ER -